Key Highlights

  • Second quarter 2026 Revenue reached USD 730,571, up 36.5% from USD 535,060 a year earlier.
  • Gross Margin widened to 41.7% from 30.5%.
  • The second quarter net loss was USD 1,506,343, compared with USD 840,933.
  • Cash stood at USD 4,546,140 on June 30, 2026, up from USD 1,025,987 at year-end 2025.
  • Reported stockholders' Equity of USD 1,620,700 sits below the USD 2,500,000 Nasdaq minimum.

20/20 Biolabs Price Action Before the Open (up USD 0.0347, 14.77%)

20/20 Biolabs (NASDAQ:AIDX) rose USD 0.0347, or 14.77%, to USD 0.2696 in pre-market trading on November 4, 2026. No Earnings release or financing announcement dated November 2 to November 4, 2026 could be found, so the catalyst is only partly clear.

The company has announced an investor webinar on Wednesday, November 4, 2026, at 12:00 p.m. Eastern, according to a press release dated October 29, 2026. The CEO is expected to discuss the OneTest Franchise program, 2027 licensing plans, roll-up acquisitions, FDA and Medicare strategy and a Maryland firefighter cancer screening effort. The release said the webinar will not cover third-quarter financial results, and the company holds the session on the first Wednesday of each month.

Company Background and Recent Results

20/20 Biolabs develops and sells laboratory-based blood tests for early detection and prevention of cancers and chronic diseases. OneTest for Cancer is a multi-cancer early detection test still under development toward FDA authorization, while OneTest for Longevity measures inflammatory biomarkers and is commercially available. Testing is performed in the company's CLIA-licensed laboratory in Gaithersburg, Maryland.

In the second quarter of 2026, revenue reached USD 730,571, up 36.5%, with OneTest revenue up 47.1% and making up 95.3% of the total. Gross Profit increased to USD 304,727 from USD 163,264. Operating expenses rose to USD 1,548,950 from USD 1,008,935, which the company mainly attributed to Nasdaq listing costs and product development.

First-half revenue of USD 1,083,946 was roughly flat against USD 1,088,880, while the first-half net loss widened to USD 3,681,180 from USD 1,605,511. Loss per share for the quarter was USD 0.26, compared with USD 0.17.

Plans, Balance Sheet and Risk Factors

The company plans to license its protein tumor marker approach to clinical laboratories in 2027 through a royalty-based franchise model, although it described interest from regional laboratories as preliminary. It has also pointed to a statutory Medicare pathway for FDA-authorized multi-cancer tests starting in 2028.

Common shares outstanding increased to 12,251,198 on June 30, 2026 from 5,442,249 on December 31, 2025, a dilution of more than 125% (calculated). The company also has Series E convertible preferred stock with a Liquidation preference of USD 6,273,600.

Nasdaq told the company on July 17, 2026 that its bid price had been below USD 1.00, with a compliance deadline of January 13, 2027. A second notice on September 3, 2026 cited stockholders' equity of USD 1,620,700 against the USD 2,500,000 requirement, a shortfall of USD 879,300 (calculated). A plan was due around October 18, 2026, and failing to regain equity compliance would remove eligibility for an extra bid-price period.

Trading under USD 1, the shares are a penny stock, a status that typically brings sharp volatility, thin Liquidity and a meaningful risk of further dilution.

Key Items to Monitor

Investors will track the webinar remarks, any update on the Nasdaq equity plan, the third-quarter Form 10-Q and any further Capital raising. Franchise agreements and FDA progress would serve as the operating milestones. Extended-hours moves in low-priced shares can reverse quickly once regular trading begins.